Indivior Inc. on Tuesday sued to block a rival drugmaker from bringing a generic version of an under-the-tongue form of Suboxone to market, after being dealt a stinging loss last month in an ongoing effort to protect its top-selling drug.

In a seven-page complaint, filed in the U.S. District Court for the District of Delaware, U.K.-based Indivior said Teva Pharmaceuticals’ subsidiary Actavis Laboratories had infringed the so-called ’305 patent for the opioid-addiction treatment with applications to develop and sell a copycat of the drug in the United States.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]